Compare · AKER vs ORKA
AKER vs ORKA
Side-by-side comparison of Akers Biosciences Inc. (AKER) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKER and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA carries a market cap of $3.42B.
- ORKA has hit the wire 6 times in the past 4 weeks while AKER has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 0 for AKER).
- Company
- Akers Biosciences Inc.
- Oruka Therapeutics Inc.
- Price
- -
- $68.97+2.03%
- Market cap
- -
- $3.42B
- 1M return
- -
- +57.38%
- 1Y return
- -
- +568.31%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 11
Latest AKER
- SEC Form S-3/A filed by Akers Biosciences Inc. (Amendment)
- SEC Form 3: Williams Caroline C claimed ownership of 5,017,423 units of Common Stock
- SEC Form 4 filed by EAGLE CRAIG
- SEC Form 3 filed by EAGLE CRAIG
- Akers Biosciences Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 4 filed by Kaplin Adam
- SEC Form 3 filed by Kaplin Adam
- SEC Form 4: Schreiber Christopher C exercised 131,750 units of Common Stock at a strike of $0.00 and disposed of $227,798 worth of Common Stock (46,113 units at $4.94), increasing direct ownership by 3,292% to 88,238 units to cover withholding tax
- SEC Form 4 filed by Uzonwanne Jude
- SEC Form 4: Chapman Christopher C JR was granted 96,475 units of Common Stock
Latest ORKA
- Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
- SEC Form 424B7 filed by Oruka Therapeutics Inc.
- SEC Form DEFA14A filed by Oruka Therapeutics Inc.
- SEC Form DEF 14A filed by Oruka Therapeutics Inc.
- SEC Form 4 filed by Goncalves Joana
- SEC Form EFFECT filed by Oruka Therapeutics Inc.
- SEC Form S-3 filed by Oruka Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Oruka Therapeutics Inc.
- Chief Executive Officer Klein Lawrence Otto sold $71,408 worth of shares (1,729 units at $41.30), decreasing direct ownership by 0.19% to 927,309 units (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun sold $16,313 worth of shares (395 units at $41.30), decreasing direct ownership by 2% to 18,863 units (SEC Form 4)